A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to Investigate the Effect of Formoterol HFA-pMDI Versus Salmeterol HFA-pMDI on Small Airways Physiological Parameters in COPD Patients
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Formoterol (Primary) ; Formoterol (Primary) ; Salmeterol; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms IMPERIAL
- Sponsors Chiesi Farmaceutici SpA
- 18 Oct 2012 Planned number of patients changed from 30 to 40 as reported by EudraCT.
- 14 Feb 2012 Planned End Date changed from 1 Mar 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 03 May 2011 New trial record